Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab

Multiple myeloma (MM) is incurable, so there is a significant unmet need for effective therapy for patients with relapsed or refractory disease. This situation has not changed despite the recent approval of the anti-CD38 antibody daratumumab, one of the most potent agents in MM treatment. The effici...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Guerrero, Estefanía, Götz, Ralph, Doose, Sören, Sauer, Markus, Rodríguez-Gil, Alfonso, Nerreter, Thomas, Kortüm, K. Martin, Pérez-Simón, José A., Einsele, Hermann, Hudecek, Michael, Danhof, Sophia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318885/
https://www.ncbi.nlm.nih.gov/pubmed/32350373
http://dx.doi.org/10.1038/s41375-020-0840-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318885/
https://www.ncbi.nlm.nih.gov/pubmed/32350373
http://dx.doi.org/10.1038/s41375-020-0840-y

Ejemplares similares